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Objectives: Lithium-treated patients with polyuria are at increased risk of lithium toxicity. We aimed to describe the clinical
benefits and risks of different management strategies for polyuria in community lithium-treated patients.
Methods: This is a naturalistic, observational, prospective 12-month cohort study of lithium-treated patients with polyuria
attending a community mental health service in Dublin, Ireland. When polyuria was detected, management changed in one of
four ways: (a) no pharmacological change; (b) lithium dose decrease; (c) lithium substitution; or (d) addition of amiloride.
Results: Thirty-four participants were diagnosed with polyuria and completed prospective data over 12 months. Mean
24-hour urine volume decreased from 4852 to 4344 ml (p = 0.038). Mean early morning urine osmolality decreased from 343 to
338 mOsm/kg (p = 0.823). Mean 24-hour urine volume decreased with each type of intervention but did not attain statistical
significance for any individual intervention group. Mean early morning urine osmolality decreased in participants with no phar-
macological change and increased in participants who received a change in medication but these changes did not attain statistical
significance. Only participants who discontinued lithium demonstrated potentially clinically significant changes in urine volume
(mean decrease 747ml in 24 hours) and earlymorning urine osmolality (mean increase 31mOsm/kg) although this was not defini-
tively proven, possibly owing to power issues.
Conclusions:Managing polyuria by decreasing lithium dose does not appear to substantially improve objective measures of renal
tubular dysfunction, whereas substituting lithium may do so. Studies with larger numbers and longer follow-up would clarify
these relationships.
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Introduction
Lithium is associated with significant long-term adverse
effects including impaired renal function (Shine
et al. 2015). Polyuria is the most common renal effect
with a 36% prevalence in community lithium patients
(Kinahan et al. 2015a). Polyuria is suggestive of renal
tubular dysfunction which results from lithium-induced
antidiuretic hormone (ADH) partial resistance (Grünfeld
& Rossier, 2009).
Lithium-treated patientswith renal tubular dysfunc-
tion are at increased risk of dehydration, lithium intoxi-
cation and progressive renal damage (Livingstone &
Rampes, 2006). There are a number of approaches to
decrease the ADH resistance in lithium-treated patients
but the clinical benefits and risks of these different
approaches have not been fully described.
Studies of lithiumpatientswith renal tubular dysfunc-
tion have demonstrated improvements in different renal
parameters through the addition of amiloride (Batlle
et al. 1985; Bedford et al. 2008), non-steroidal anti-inflam-
matory medications (Berl et al. 1977; Stokes, 1981) and
thiazides (Bichet, 2017). Dose reduction has been recom-
mended on the basis that higher lithium doses
(Vestergaard et al. 1979; Lokkegaard et al. 1985; Bendz
et al. 1994) and concentrations (Waller et al. 1984) are asso-
ciated with renal tubular dysfunction (Martin, 1993;
Malhi & Tanious, 2011; Malhi et al. 2011). Substituting
lithium with an alternative psychotropic is another strat-
egy and improvements in different renal parameters
have been demonstrated (Vestergaard&Amdisen, 1981).
This study aimed to describe the clinical benefits
and risks ofmanaging polyuria in different ways in lith-
ium-treated patients.
Methods
This is a naturalistic prospective observational cohort
study of lithium-treated patients at the Cluain Mhuire
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Community Mental Health Service, in Dublin, Ireland.
All patients who were prescribed lithium during a
1-month period were recruited. Participants completed
a 24-hoururine collection.All participantsdiagnosedwith
polyuria (i.e. 24-hour urine collection ≥3 l) (Bichet, 2017)
were included in the prospective cohort study.
This study was conducted following a cross-
sectional study investigating risk factors and methods
of detecting polyuria in lithium-treated patients
(Kinahan et al. 2015a, 2015b). After providing informed
consent, participants were given clear instructions for
completing a 24-hour urine collection, early morning
urine sample and symptom questionnaire. Urine was
collected at home during a convenient 24-hour period.
Participants completed the early morning urine sample
on the first void of the day. After recording this time
(when the bladder was empty), subsequent urine was
collected for following 24 hours including the final void
which was as close as possible (but not after) the
recorded time. Participants were advised not to change
or restrict their fluid intake during the tests.
After the collection was completed, a questionnaire
was posted to patients, asking about the subjective
presence of polyuria, polydipsia and nocturia, and
the severity of each on a scale of increasing severity
(0–3). The frequency of episodes of clinically significant
mooddisturbances over the 12-month period preceding
urine collection was extracted from medical records.
The results of the 24-hour urine collection were for-
warded to the participant’s treating psychiatric team.
For participants diagnosed with polyuria, the treating
team in collaborationwith the participant changed their
management in one of four ways: (a) education alone:
the participant was educated about the risks of polyuria
but there was no pharmacological change; (b) dose
decrease: the participant was educated about the risks
of polyuria and the dose of lithium was decreased; (c)
stop lithium: the participant was educated about the
risks of polyuria and lithium was replaced with an
alternative psychotropic; or (d) addition of amiloride:
the participant was educated about the risks of polyuria
and amiloride was added to lithium (Martin, 1993).
Twelve months after diagnosis with polyuria, partici-
pants repeated the 24-hour urine collection, earlymorn-
ing urine sample and symptom questionnaire.
Anonymised data were stored and described using
IBMSPSS Statistics (Version 24). Changes in continuous
variables were tested using Paired t-test or Wilcoxon
signed rank test, as appropriate.
Results
One hundred and thirty-eight patients were treated
with lithium during the month of recruitment to the
study. Forty-three participants were diagnosed with
polyuria (31.1%) and included in the prospective study.
Initial data were complete for 39 participants (90.7%)
and 34 (79.1%) completed the 24-hour urine collection
12 months after diagnosis (one of which was inaccurate
due to hyperglycemia). Of these 34 participants, 26
(76.5%) completed the questionnaires and 28 (82.4%)
completed the early morning urine osmolality. Mean
age of the participants diagnosed with polyuria was
46 years (Table 1). The characteristics of the participants
who completed the second 24-hour urine collection (n=
34) did not differ from the full group initially diagnosed
with polyuria (n = 43).
Of the 34 polyuric participants who completed two
24-hour urine collections, 25 remained polyuric (73%)
(Tables 2 and 3). Mean 24-hour urine volume decreased
from 4852 to 4344 ml (p = 0.038) and mean early
morning urine osmolality decreased from 343 to 338
mOsm/kg (p = 0.823). The proportions of participants
with subjective complaints of polyuria (59% v. 56%) or
nocturia (68% v. 56%) did not change substantially but
the proportionwith subjective complaints of polydipsia
appeared to decrease (65% v. 44%).
Eight participants (24%) were no longer polyuric
after the interventions: 13% of participants who had
no pharmacological change; 12% of those whose
lithium dose was decreased; and 55% of those whose
lithium was stopped (Table 4). We do not draw any
conclusions about amiloride as only one patient
received it. Mean 24-hour urine volume decreased
with each type of intervention but this decrease did
not attain statistical significance for any individual
intervention group. The largest mean change in
volume was in the participants whose lithium was
stopped (mean decrease 747 ml). Of these, five had
been treated for more than 10 years and four for fewer.
There was no significant difference in change in urine
volume after stopping lithium between these groups
(decreases of 792 and 689 ml, respectively).
Mean early morning urine osmolality decreased in
participants with no pharmacological change and
increased in participants who received a change in
medication, but these changes did not attain statistical
significance. The proportion of participants reporting
the presence of the three symptoms appeared to dimin-
ish after all the interventions apart from the participants
whose lithium was stopped (14% more of these partic-
ipants complained of polyuria). The largest potential
changes occurred in participants whose lithium was
stopped (57% no longer reported polydipsia), but this
group also experiencedmore manic episodes (although
this was not significant). Admissions and all mood epi-
sodes appeared to tend to increase in participants
whose lithium dose was decreased.
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Discussion
Objective parameters of renal tubular dysfunction
appear broadly stable 12 months after diagnosis of pol-
yuria in lithium-treated patients. Decreasing lithium
dose does not appear to be associatedwith a substantial
improvement in renal tubular dysfunction but may be
associated with a slight improvement in the symptoms
of polyuria and an increase in psychiatric morbidity.
Stopping lithium may be associated with substantial
improvement in renal tubular dysfunction and
improvement in the symptoms of polydipsia but an
increase in psychiatric morbidity.
In our subgroup of polyuric patients who received
no pharmacological change (education only), mean
24-hour urine volume decreased slightly but not signifi-
cantly. For patients who remain on lithium, similar or
increased urine volumes have been demonstrated over
time in the past (Vestergaard &Amdisen, 1981; Hetmar
et al. 1987). Early morning urine osmolality, a surrogate
marker for maximum renal concentrating capacity,
decreased marginally but not significantly in our edu-
cation only subgroup, and there was also no change
in severity of polyuria, polydipsia and nocturia. This
is consistentwith studies showing no significant change
in nocturia and various other symptoms over time
(Vestergaard & Amdisen, 1981).
Several studies have demonstrated positive correla-
tions between lithium dose and urine volume
(Vestergaard et al. 1979; DePaulo et al. 1984; Lokkegaard
et al. 1985) and negative correlations between dose
and maximal urine osmolality (Waller et al. 1984;
Lokkegaard et al. 1985; Bendz et al. 1994). In our study,
mean 24-hour urine volume decreased slightly but not
significantly in participants with dose reduction, and
mean early morning urine osmolality remained rela-
tively stable. The proportion reporting symptoms
appeared to decrease but there appeared to be an
increase in psychiatric morbidity. In contrast, the stop
lithium subgroup’s change in urine volume appeared
to be greater than those of the education only and dose
decrease subgroups.
Substituting lithium with an alternative psycho-
tropic has the potential to reverse the ADH resistance
although a long-term defect can persist (Bendz et al.
1996; Garofeanu et al. 2005). After lithium withdrawal,
24-hour urine volume has been reported to decrease
significantly (Vestergaard & Amdisen, 1981) although
stability of the 24-hour urine volume has also been doc-
umented (Hetmar et al. 1991).
Rej et al. (2012), in a systematic review, concluded
that there was little systematic evidence to suggest that
lithium withdrawal was beneficial in chronic renal fail-
ure. One study examined 46 patients who had lithium
discontinued and found that after 3 months mean urine
volume decreased by 0.6 l per 24 hours (similar to the
decrease in our stop lithium group: 0.7 l) and mean
early morning urine osmolality increased by 76
mOsm/kg (similar to, but greater than, the increase
we observed: 31 mOsm/kg) (Bendz, 1985). Bucht &
Wahlin (1980) reported on 87 patients in whom lithium
Table 1. Characteristics of adult patients with polyuria during lithium treatment at a general adult psychiatry service over a 1-month period
Variable
All patients with
polyuria
(n = 43)
Participants who
completed second 24-hour
urine collection
(n = 34)
Participants who did not
complete second 24-hour
urine collection
(n = 9)
Age in years
mean (range)
46 (22–66) 45 (22–64) 51 (31–66)
Gender, n (%) Female 23 (53) 15 (44) 8 (89)
Male 20 (47) 19 (56) 1 (11)
Weight metrics
mean (range)
Body mass index, (kg/m2) 31 (21–41) 31 (21–42) 30 (24–39)
Total body weight, (kg) 92 (57–130) 92 (57–130) 86 (70–105)
Lithium
mean (range)
Dose, (mg) 902 (400–1800) 938 (400–1800) 767 (500–1000)
Concentration, (mmol/l) 0.66 (0.2–1.26) 0.65 (0.2–1.3) 0.66 (0.5–1)
Duration of use, (years) 12 (0.5–35) 12 (0.5–35) 12 (3–30)
Diagnosis, n (%) Bipolar affective disorder 29 (68) 23 (68) 6 (67)
Depression 4 (9) 3 (9) 1 (11)
Schizoaffective disorder 10 (23) 8 (23) 2 (22)
Medications, n (%) Antidepressants 21 (49) 14 (41) 7 (78)
Antipsychotics 29 (67) 22 (65) 7 (78)
Benzodiazepines 17 (40) 12 (35) 5 (56)
Antiepileptics 14 (33) 12 (35) 2 (22)
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Table 2. Characteristics of adult patients in a preliminary prospective observational study of polyuria management during lithium treatment who completed two 24-hour urine collections 12 months apart,
stratified by polyuria management strategy
Variable
All patients with
polyuria
(n = 34)
Polyuria management strategy
Education
alone
(n = 16)
Education and
decrease
lithium dose
(n = 8)
Education and replace
lithium with another
psychotropic
(n = 9)
Education and add
amiloride to lithium
(n = 1)
Diagnosis Bipolar affective disorder, n (%) 23 (68) 11 (69) 5 (62) 6 (67) 1 (100)
Depression, n (%) 3 (9) 1 (6) 0 (0) 2 (22) 0 (0)
Schizoaffective disorder, n (%) 8 (23) 4 (25) 3 (38) 1 (11) 0 (0)
Baseline characteristics Age, (years)
mean (range)
45
(22–64)
41
(22–59)
48
(27–63)
48
(28–64)
46
Male gender, n (%) 19 (56) 9 (56) 4 (50) 5 (56) 1 (100)
Total body weight, (kg)
mean (range)
92
(57–130)
88
(65–106)
92
(57–120)
98
(80–115)
130
Lithium dose, (mg)
mean (range)
938
(400–1800)
912
(400–1800)
1012
(800–1200)
844
(600–1600)
1600
Lithium concentration, (mmol/l)
mean (range)
0.65
(0.2–1.3)
0.6
(0.4–0.8)
0.84
(0.5–1.3)
0.56
(0.2–0.8)
0.84
Duration of lithium use, (years)
mean (range)
12
(0.5–35)
10
(0.5–30)
16
(7–35)
9
(1–22)
28
Characteristics change
over 12-month period
since diagnosis of
polyuria
Lithium dose, (mg)
mean (range)
−88
(600–200)
þ25
(0–200)
−250
(200–400)
(Lithium stopped) −600
Concentration, (mmol/l)
mean (range)
−0.07
(−0.6–0.3)
þ0.02
(−0.5–0.3)
−0.22
(0.2–0.6)
(Lithium stopped) −0.25
Toxicity, n (%) 1 (3) 0 1 (12) (Lithium stopped) 0
Referral to specialist Overall, n (%) 7 (21) 1 (6) 1 (12) 4 (44) 1 (100)
Endocrinology, n (%) 2 (6) 0 0 2 (22) 0
Nephrology, n (%) 5 (15) 1 (6) 1 (12) 2 (22) 1 (100)
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was discontinued and found that concentrating capac-
ity improved significantly during the first 2 months
after withdrawal but not later; after 1 year, 17 of 27
patients still had concentrating capacities below 800
mOsm/kg. All patients in our study had concentrating
capacities below 800 mOsm/kg at both time points.
Vestergaard &Amdisen (1981) reported that lithium
discontinuation resulted in normalisation of urine vol-
ume and improvement (but not normalisation) of maxi-
mum urine osmolality, while Bendz et al. (1996)
followed up 13 lithium discontinuation patients for 9
weeks and found that concentrating capacity did not
improve at all after discontinuation. In patients pre-
scribed lithium for over 15 years, Bendz et al. (1996)
reported that urine volume increased but the propor-
tion of patients who were polyuric (50%) remained sta-
ble before and after lithium withdrawal. A similar
finding was reported by Boton et al. (1987) when the
duration of lithium treatmentwas greater than 10 years.
In our study, of the nine patientswhose lithiumwas dis-
continued, five had been treated with lithium for
greater than 10 years and four for fewer, but there
was no significant difference in the change in urine vol-
ume after stopping lithium between these groups.
Also in our study, mean early morning urine osmo-
lality appeared to increase after stopping lithium, but
this change was not significant and contrasted with
the apparent decrease in the education only subgroup.
Lithium withdrawal studies have previously reported
increases in maximal urine osmolality (Hetmar et al.
1991), but in one sample of patients prescribed lithium
for at least 15 years the maximal urine osmolality was
stable (Bendz et al. 1994, 1996).
Previous research has also explored symptoms of
lithium patients initially and after a mean of 1.7 years
(Vestergaard et al. 1980; Vestergaard & Amdisen,
1981); after lithiumwithdrawal, only 30% reported pol-
ydipsia compared to 70% initially. In our study, the pro-
portion of the stop lithium subgroup who reported
polydipsia decreased by 57% over 12 months. The pro-
portion who reported polyuria increased by 14%, and
there was no change in the proportion reporting noctu-
ria. In addition, the stop lithium subgroup appeared to
experience more manic episodes over the 12-month
Table 3. Changes in prospective outcome measures among adult patients in a preliminary prospective observational study of polyuria
management during lithium treatment
Variable
First 24-hour
urine collection
(pre-intervention)
Second 24-hour
urine collection
(post-intervention) Change
Urine output
(n = 33)
Polyuric, n (%) 34 (100) 25 (73) −8 (−24)
24-hour urine volume, (ml)
mean (range)
4852 (3025–10,293) 4344 (1368–10,486) −555 (−4312–2851)
p = 0.038
Early morning urine osmolality,
(mOsm/kg)
mean (range)
343 (120–794) 338 (112–722) −6 (432 to þ267)
p = 0.823
Subjective
responses
(n = 26)
Polyuric, n (%) 20 (59) 19 (56) −2 (−8)
Severity of polyuria (0–3, with
3 indicating more severe polyuria)
median (range)
2 (0–3) 2 (0–3) 0 (−3 to þ2)
Polydipsia present, n (%) 22 (65) 15 (44) −7 (−27)
Severity of polydipsia (0–3, with 3
indicating more severe polydipsia)
median (range)
1.5 (0–3) 1 (0–3) 0 (−3 to þ2)
Nocturia present, n (%) 23 (68) 19 (56) −3 (−12)
Severity of nocturia (0–3, with 3
indicating more severe nocturia)
median (range)
1 (0–2) 1 (0–2) 0 (−1 to þ1)
Psychiatric morbidity
in the 12 months
preceding the
24-hour urine
collection
(n = 33)
Number of admissions
mean (range)
0.21 (0–2) 0.26 (0–3) þ0.06 (−2 to þ3)
Number of manic episodes
mean (range)
0.24 (0–1) 0.33 (0–2) þ0.09 (−1 to þ2)
Number of depressive episodes
mean (range)
0.27 (0–3) 0.18 (0–1) −0.09 (−3 to þ1)
Number of all mood episodes
mean (range)
0.51 (0–3) 0.51 (0–3) 0 (−2 to þ2)
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Table 4. Changes in prospective outcome measures among adult patients in a preliminary prospective observational study of polyuria management during lithium treatment stratified by polyuria management
strategy
Variable
Polyuria management strategy
Education alone
(n= 16)
Education and
decrease lithium
dose
(n= 8)
Education and replace
lithium with another
psychotropic
(n = 9)
Education and
add amiloride to
lithium
(n= 1)
Urine output (n= 33) Change in number polyuric, n (%) −2 (−13) −1 (−12) −5 (−55) 0
Change in 24-hour urine volume, (ml)
mean (range)
−440 (−4312–2719) −497 (−2068–1075) −747 (−2632–2851) −1038
Mean 24-hour urine volume: before–after
(p-value)
4684–4244 (0.286) 5488–4991 (0.236) 4138–3391 (0.261) 10,293–9255
(0.317)
Change in early morning urine osmolality, (mOsm/kg)
mean (range)
−27 (−432 to þ213) þ2.6 (−25 to þ39) þ31 (−88 to þ267) þ29
Mean early morning urine
osmolality: before–after
(p-value)
380–352 (0.521) 229–232 (0.844) 365–396 (0.538) 130–159 (0.317)
Subjective responses (n = 26) Change in number polyuric, n (%) −2 (−15) −1 (−20) þ1 (þ14) 0
Change in severity of polyuria (0–3, with
3 indicating more severe polyuria)
median (range)
0 (−3 to þ1) 0 (−2 to þ2) 0 (−2 to þ1) 0
Change in number with polydipsia, n (%) −2 (−15) −1 (−20) −4 (−57) 0
Change in severity of polydipsia (0–3, with
3 indicating more severe polydipsia)
median (range)
0 (−2 to þ2) 1 (−2–0) 1 (−3–0) 0
Nocturia present, n (%) −3 (−23) 0 0 0
Change in severity of nocturia (0–3, with
3 indicating more severe nocturia)
median (range)
0 (−1 to þ1) 0 (−1–0) 0 (−1–1) 1
Psychiatric morbidity (n = 33) Change in number of admissions
mean (range)
−0.06 (−2 to þ3) þ0.5 (−2 to þ1) −0.1 (−2 to þ1) 0
Change in number of manic episodes
mean (range)
þ0.06 (−1 to þ2) þ0.14 (−1 to þ1) þ0.11 (−1 to þ1) 0
Change in number of depressive episodes
mean (range)
−0.31 (−3 to −1) þ0.43 (−2 to þ1) −0.11 (−2 to þ1) 0
Change in number of all mood episodes
mean (range)
−0.25 (−2 to þ2) þ0.57 (−1 to þ2) 0 (−2 to þ2) 0
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period since stopping, although the significance of this
is not established.
Limitations of this study
This was not a controlled study. As a naturalistic study
the intervention the participant received depended on a
number of factors that may influence the outcomes of
interest (co-morbid illness, participant preferences,
etc.). Urine volume, polyuria and early morning urine
osmolality are all parameters of renal tubular dysfunc-
tion but do not diagnose the tubular dysfunction. We
used the Bichet’s (2017) definition of polyuria as a urine
volume ≥3 l in 24 hours. Volume of urine is, however,
potentially subject to many other variables, such as
weight, gender and age, and, in a larger study, it would
have been possible to control these factors through study
design or multi-variable analysis. It is hoped to do so
in future work using the International Continence
Society’s definition of polyuria as 40 ml of urine or more
per kilogram body weight over 24 hours.
In addition, we did not establish the cause of the
polyuria; a proportionof casesmight be explainedbypri-
mary polydipsia as opposed to a urinary concentrating
deficit. Previous studies demonstrated the prevalence
of a urinary concentrating deficit in polyuric lithium-
treated patients as between 77% and 91% (Forrest et al.
1974; Vestergaard et al. 1979; Bendz et al. 1994). A water
deprivation test definitively diagnoses renal tubular
dysfunction but is limited by its practicality in routine
clinical settings (such as the setting of this study).
The accuracy of the 24-hour collections was not con-
firmed in this study and neither was the accuracy of the
early morning urine osmolality. Participants were,
however, given clear verbal and written instructions
and advised not to withhold fluid intake overnight.
We used early morning urine to estimate maximum
concentrating capacity but this may be affected by noc-
turia in certain patients. Ideally, a larger study would
control for nocturia at design or analysis stages but this
was not feasible in ourwork given the size of our study.
We found that the mean decrease in lithium concen-
trationwas 0.22mmol/l, and this might not be sufficient
to result in significant changes in urine osmolality and
urine volume, thus possibly explaining the lack of differ-
entiation between stopping lithium and just reducing
the dose.
The small numbers of participants in our study pre-
vent robust interpretation of inferential statistics.
Studies with larger numbers of participants would
facilitate more penetrating statistical analysis to deter-
mine if the differences described in this study are due
to chance alone and permit greater examination of
themanagement options. Our studywas an observatio-
nal studywith fourmanagement branches rather than a
randomised trial capable of delivering definitive
answers about the merits and demerits of alternative
management options.
Finally, our sample might not be representative of
the general population, and length of follow-up was
limited to 1 year. It is not, however, conclusively known
how long it takes to induce or reverse the renal changes
caused by lithium, and it should be noted that most
studies that have investigated treating lithium-induced
renal tubular dysfunction have demonstrated improve-
ment within a much shorter time frame (Berl et al. 1977;
Stokes, 1981; Batlle et al. 1985; Bedford et al. 2008).
Conclusions
Our paper underlines the fact that lithium-induced pol-
yuria is a significant and substantial problem among
patients treated with lithium. We found that, without
pharmacological intervention, objective parameters of
renal tubular dysfunction appear broadly stable 12
months after diagnosis of polyuria. Managing polyuria
by decreasing lithium dose does not appear to substan-
tially improve objective measures of renal tubular
dysfunction, whereas substituting lithium may do so,
although both interventions may be associated with
increased psychiatric morbidity. Looking to the future,
controlled and adequately powered studies are required
to establish the relative benefits of different methods of
managing polyuria in lithium-treated patients. There is
also a need for more work examining in greater depth
the background to polyuria in lithium-treated patients
in the first instance.
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